Cardiac Amyloidosis Research
Cardiac amyloidosis, particularly ATTR (transthyretin) amyloidosis, is a progressive condition where abnormal protein deposits impair the heart’s function, often leading to heart failure. At CliniQuest Research Site, an initiative of CRK-NGO and based in St. Mary’s Mission Hospital, Nairobi, we are dedicated to advancing research, early diagnosis, and access to innovative therapies. With a comprehensive ecosystem that includes clinics, laboratories, pharmacies, patient recruitment, data management, and regulatory support, we provide a trusted hub for amyloidosis clinical trials in Kenya and across Africa.
Our approach to tackling cardiac amyloidosis is comprehensive, addressing the full spectrum of patient needs:
Early Detection in ATTR Cardiac Amyloidosis
We use advanced echocardiography, ECG, and biomarker testing to identify cardiac amyloidosis early, even in resource-limited settings.
Innovative Therapies for TTR Amyloidosis Research
Partnering with global sponsors, we evaluate stabilizers, silencers, and emerging therapies that can slow disease progression.
Patient Recruitment & Retention
Our dedicated department engages diverse communities, ensuring equitable access to clinical trials for underserved populations.
Real-World Data & Outcomes
By integrating clinical data, laboratory results, and pharmacovigilance, we contribute meaningful insights to global amyloidosis research.
Located in the heart of Nairobi, CliniQuest offers all essential departments under one roof:
Specialized Clinics for Amyloidosis Patients – Dedicated care for screening, enrollment, and follow-up.
Laboratory & Biostatistics in Amyloidosis Studies – Sample testing, data management, and biomarker research for reliable outcomes.
Pharmacy – for investigational product storage, dispensing, and monitoring.
Patient Recruitment Department – bridging clinical research with community outreach.
Data Management & Biostatistics – ensuring high-quality data and robust analysis.
Regulatory Affairs & Compliance – navigating ethics and approvals with the Pharmacy and Poisons Board (PPB) and NACOSTI.
Training & Education – building Kenya’s capacity in rare disease research and GCP standards.
We collaborate with:
Kenyan cardiologists and hospitals to strengthen local diagnostic capacity.
Global research networks and sponsors to bring cutting-edge therapies to Kenya.
Patient advocacy groups to ensure awareness and timely referrals for suspected cases.
These partnerships make CliniQuest a strategic site for cardiac amyloidosis clinical trials in Africa.
Our Partners in Cardiac Amyloidosis Research
Why Choose CliniQuest for Cardiac Amyloidosis Studies?
Full-service research site
Full-service research site with clinics, labs, pharmacy, and recruitment units.
Expertise in rare disease trials
Expertise in rare disease trials, ensuring ethical and scientifically rigorous conduct.
Proximity to underserved populations
Proximity to underserved populations enables access to diverse participants.
Commitment to equity
Commitment to equity, bringing innovative therapies closer to patients who need them most.
CliniQuest Research Site invites sponsors, investigators, and collaborators to partner with us in the fight against cardiac amyloidosis. Together, we can improve early diagnosis, expand treatment options, and transform the future of care for patients in Kenya and beyond.
To learn more about our cardiac amyloidosis research or explore opportunities for collaboration, please get in touch with us at contact@cliniquest.org
Your support and involvement are crucial as we tackle one of the most pressing health threats of our time.